Trial · NCT00385580
Results by group249
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 249
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With a Response | Dasatinib 100 mg Once Daily (QD) | 12 | participants | ||
| Number of Participants With a Response | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 13 | participants | ||
| Percentage of Participants With a Response | Dasatinib 100 mg Once Daily (QD) | 25.00 | 95% Confidence Interval 13.64 to 39.60 | Percentage of Participants | |
| Percentage of Participants With a Response | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 27.70 | 95% Confidence Interval 15.62 to 42.64 | Percentage of Participants | |
| Number of Participants With a Decrease in PSA by at Least 50% From Baseline | Dasatinib 100 mg Once Daily (QD) | 1 | participants | ||
| Number of Participants With a Decrease in PSA by at Least 50% From Baseline | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 1 | participants | ||
| Percentage of Participants With a Decrease in PSA by at Least 50% From Baseline | Dasatinib 100 mg Once Daily (QD) | 2.3 | Percentage of Participants | ||
| Percentage of Participants With a Decrease in PSA by at Least 50% From Baseline | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 2.3 | Percentage of Participants | ||
| Number of Months of Decrease in PSA by at Least 50% From Baseline | Dasatinib 100 mg Once Daily (QD) | 0.82 | months | ||
| Number of Months of Decrease in PSA by at Least 50% From Baseline | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 11.17 | months | ||
| Number of Participants With Decrease in PSA Velocity | Dasatinib 100 mg Once Daily (QD) | 25 | -0.4 to 5.7 | participants | |
| Number of Participants With Decrease in PSA Velocity | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 16 | -0.2 to 13.2 | participants | |
| Number of Participants With Decrease in PSA Log Slope | Dasatinib 100 mg Once Daily (QD) | 38 | -0.015 to 0.018 | participants | |
| Number of Participants With Decrease in PSA Log Slope | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 34 | -0.008 to 0.029 | participants | |
| Number of Participants With Increase in PSA Doubling Time | Dasatinib 100 mg Once Daily (QD) | 34 | 39.0 to 858.0 | participants | |
| Number of Participants With Increase in PSA Doubling Time | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 32 | 24.0 to 2622.0 | participants | |
| Number of Participants With CR or PR | Dasatinib 100 mg Once Daily (QD) | 1 | participants | ||
| Number of Participants With CR or PR | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 0 | participants | ||
| Number of Participants With CR, PR or SD | Dasatinib 100 mg Once Daily (QD) | 11 | participants | ||
| Number of Participants With CR, PR or SD | Dasatinib 100 mg or 70 mg Twice Daily (BID) | 12 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00385580/results